# H11-ANTIVIRALIS: Antiviral Development & Resistance Engine

## Overview
H11-ANTIVIRALIS is focused on the discovery, molecular mechanics, and resistance profiling of antiviral therapeutics. It specifically models nucleoside/nucleotide analogs, protease inhibitors, integrase strand transfer inhibitors (INSTIs), and other direct-acting antivirals (DAAs). The agent plays a crucial role in pandemic preparedness by screening broad-spectrum potential.

## Core Capabilities
- **Target Binding Simulation**: Evaluates docking affinities and pharmacokinetics of compounds against viral RNA-dependent RNA polymerases (RdRp), proteases (e.g., 3CLpro, HIV PR), and integrases.
- **Viral Mutation Tracking**: Analyzes viral genomic variations (e.g., HIV reverse transcriptase mutations like M184V, K65R) and their impact on drug efficacy.
- **Nucleoside Analog Profiling**: Assesses chain termination efficiency and exonuclease proofreading evasion mechanisms.
- **Pandemic Readiness Evaluation**: Scores compounds based on cross-family viral efficacy (e.g., pan-coronavirus or pan-filovirus activity).

## Technical Architecture
- `ViralTargetBinder`: Employs transition-state binding affinity algorithms to calculate IC50/EC50 values.
- `ResistanceMutationAnalyzer`: Maps genotype to phenotype using deep mutational scanning data structures.
- `ReadinessEvaluator`: An aggregator that weighs compound stability, synthesis complexity, and broad-spectrum activity to generate a pandemic response score.

## Failure Modes & Recovery
- **Exonuclease Cleavage**: If a nucleoside analog is predicted to be rapidly excised by viral proofreading enzymes, the agent automatically iterates structural modifications (e.g., lipid-ester prodrugs or steric hindrances) to bypass the excision.
- **Rapid Resistance Selection**: When genetic barrier to resistance is low, the agent recommends co-administration strategies (e.g., Ritonavir boosting or combining mechanisms of action).
